NuVision Biotherapies
PrivateLast Round
Early Funding
Feb 5, 2026
Total Funding Raised
$7.81M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NuVision Biotherapies operates in Healthcare & Life Sciences and is based in Nottingham. Its latest recorded funding round was an Early Funding round in February 2026.
NuVision Biotherapies is a biotechnology company that develops and manufactures ophthalmic therapy products designed to offer surgeons new therapies for ocular care.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2G
Customer Profile
Hardware Sales, Government Contracts, Freemium
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NuVision Biotherapies Comparables
Compare NuVision Biotherapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioTissue | 84% | |
| Merakris Therapeutics | 78% | |
| Corza Medical | 76% |
For institutional investors. Book with your work email.
NuVision Biotherapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Feb 5, 2026 | ||||
| VC Round | Mar 8, 2023 | ||||
| VC Round | Jul 15, 2021 | ||||
| Seed | Feb 8, 2018 | ||||
| Seed | Jul 28, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NuVision Biotherapies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pioneer Group | VC Round, Early Funding |
| British Business Bank | VC Round, Early Funding |
| Mercia Ventures | Early Funding |
| Mercia Asset Management | VC Round |
| Mercia Ventures | VC Round |
| The University of Nottingham | Seed, VC Round, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 5, 2026
Raised $6.5M in early funding.
- Jan 31, 2025
Launched a new clinical product despite manufacturing challenges.
For institutional investors. Book with your work email.
NuVision Biotherapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NuVision Biotherapies's valuation, stock price, and market status.
Is NuVision Biotherapies a public or private company?
NuVision Biotherapies is a private company.
What is the current stock price of NuVision Biotherapies?
NuVision Biotherapies is a private company, so its shares have no public market price. Caplight tracks NuVision Biotherapies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NuVision Biotherapies worth (valuation)?
Valuation information for NuVision Biotherapies is not publicly available.
Can I buy NuVision Biotherapies stock?
NuVision Biotherapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NuVision Biotherapies's last funding round?
NuVision Biotherapies's most recent funding round was Early Funding on February 5, 2026.
Who are the main investors in NuVision Biotherapies?
Key investors in NuVision Biotherapies include Mercia Ventures, Mercia Asset Management.
Will NuVision Biotherapies IPO soon?
No public IPO plans have been announced for NuVision Biotherapies.
How can I track NuVision Biotherapies secondary market activity?
Caplight tracks bids, offers, and trades in NuVision Biotherapies's shares on secondary markets.